Benzinga.com: Prytime Medical Announces the Launch of the PROMPT Observational Clinical Trial, the first prospective in-human study of Partial REBOA U.S. Department of Defense awards Prytime Medical grant to study the clinical outcomes of the world's first and only catheter designed for Partial REBOA, pREBOA-PRO™ Prytime Medical Inc, The REBOA ... Prytime Medical Announces the Launch of the PROMPT Observational Clinical Trial, the first prospective in-human study of Partial REBOA Reboa Medical As is a Norwegian company focused on developing innovative products for Resuscitative Endovascular Balloon Occlusion of Aorta (Reboa).
The products have been developed in close collaboration with experienced doctors with more than ten years of experience in temporary occlusion of aorta. REBOA was developed as a rapidly deployable, minimally invasive alternative to emergency thoracotomy with aortic cross-clamping. Although there is no single indication criteria for the procedure, it is typically performed for patients with either blunt or penetrating traumatic injuries to the torso with severe hemorrhage refractory to blood ... REBOA is Resuscitative Endovascular Balloon Occlusion of the Aorta It involves placement of an endovascular balloon in the aorta to control haemorrhage and to augment afterload in traumatic arrest and haemorrhagic shock states O Reboa tem sido usado de forma eficaz para interromper o sangramento em pessoas com trauma grave em regiões como tórax e abdômen REBOA technology was adapted from endovascular surgery where balloons have been used for many years for "ironing" out the fabric of stent grafts used to treat aortic aneurysms.
